BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26384561)

  • 1. Molecular basis of the attenuated phenotype of human APOBEC3B DNA mutator enzyme.
    Caval V; Bouzidi MS; Suspène R; Laude H; Dumargne MC; Bashamboo A; Krey T; Vartanian JP; Wain-Hobson S
    Nucleic Acids Res; 2015 Oct; 43(19):9340-9. PubMed ID: 26384561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse APOBEC1 cytidine deaminase can induce somatic mutations in chromosomal DNA.
    Caval V; Jiao W; Berry N; Khalfi P; Pitré E; Thiers V; Vartanian JP; Wain-Hobson S; Suspène R
    BMC Genomics; 2019 Nov; 20(1):858. PubMed ID: 31726973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage.
    Caval V; Suspène R; Shapira M; Vartanian JP; Wain-Hobson S
    Nat Commun; 2014 Oct; 5():5129. PubMed ID: 25298230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear Magnetic Resonance Structure of the APOBEC3B Catalytic Domain: Structural Basis for Substrate Binding and DNA Deaminase Activity.
    Byeon IJ; Byeon CH; Wu T; Mitra M; Singer D; Levin JG; Gronenborn AM
    Biochemistry; 2016 May; 55(21):2944-59. PubMed ID: 27163633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AID, APOBEC3A and APOBEC3B efficiently deaminate deoxycytidines neighboring DNA damage induced by oxidation or alkylation.
    Diamond CP; Im J; Button EA; Huebert DNG; King JJ; Borzooee F; Abdouni HS; Bacque L; McCarthy E; Fifield H; Berghuis LM; Larijani M
    Biochim Biophys Acta Gen Subj; 2019 Nov; 1863(11):129415. PubMed ID: 31404619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthologous mammalian APOBEC3A cytidine deaminases hypermutate nuclear DNA.
    Caval V; Suspène R; Vartanian JP; Wain-Hobson S
    Mol Biol Evol; 2014 Feb; 31(2):330-40. PubMed ID: 24162735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.
    Matsumoto T; Shirakawa K; Yokoyama M; Fukuda H; Sarca AD; Koyabu S; Yamazaki H; Kazuma Y; Matsui H; Maruyama W; Nagata K; Tanabe F; Kobayashi M; Shindo K; Morishita R; Sato H; Takaori-Kondo A
    Sci Rep; 2019 Jun; 9(1):8307. PubMed ID: 31165764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation.
    Xiao X; Yang H; Arutiunian V; Fang Y; Besse G; Morimoto C; Zirkle B; Chen XS
    Nucleic Acids Res; 2017 Jul; 45(12):7494-7506. PubMed ID: 28575276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3A is a prominent cytidine deaminase in breast cancer.
    Cortez LM; Brown AL; Dennis MA; Collins CD; Brown AJ; Mitchell D; Mertz TM; Roberts SA
    PLoS Genet; 2019 Dec; 15(12):e1008545. PubMed ID: 31841499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA cytosine and methylcytosine deamination by APOBEC3B: enhancing methylcytosine deamination by engineering APOBEC3B.
    Fu Y; Ito F; Zhang G; Fernandez B; Yang H; Chen XS
    Biochem J; 2015 Oct; 471(1):25-35. PubMed ID: 26195824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-Angle X-ray Scattering Models of APOBEC3B Catalytic Domain in a Complex with a Single-Stranded DNA Inhibitor.
    Barzak FM; Ryan TM; Kvach MV; Kurup HM; Aihara H; Harris RS; Filichev VV; Harjes E; Jameson GB
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33673243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing preferences of human APOBEC3A and APOBEC3B for cytosines in hairpin loops, and reflection of these preferences in APOBEC-signature cancer genome mutations.
    Butt Y; Sakhtemani R; Mohamad-Ramshan R; Lawrence MS; Bhagwat AS
    Nat Commun; 2024 Mar; 15(1):2369. PubMed ID: 38499553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B.
    Shi K; Demir Ö; Carpenter MA; Wagner J; Kurahashi K; Harris RS; Amaro RE; Aihara H
    Sci Rep; 2017 Dec; 7(1):17415. PubMed ID: 29234087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
    Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
    PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the Enzyme-Substrate Properties for APOBEC3A-Mediated RNA Editing.
    Kim K; Shi AB; Kelley K; Chen XS
    J Mol Biol; 2023 Sep; 435(17):168198. PubMed ID: 37442413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.
    Cheng AZ; Moraes SN; Attarian C; Yockteng-Melgar J; Jarvis MC; Biolatti M; Galitska G; Dell'Oste V; Frappier L; Bierle CJ; Rice SA; Harris RS
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31534038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1.
    Ooms M; Krikoni A; Kress AK; Simon V; Münk C
    J Virol; 2012 Jun; 86(11):6097-108. PubMed ID: 22457529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B.
    Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS
    PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of point mutations in the cytidine deaminase domains of APOBEC3B on replication and hypermutation of hepatitis B virus in vitro.
    Bonvin M; Greeve J
    J Gen Virol; 2007 Dec; 88(Pt 12):3270-3274. PubMed ID: 18024895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient deamination of 5-methylcytidine and 5-substituted cytidine residues in DNA by human APOBEC3A cytidine deaminase.
    Suspène R; Aynaud MM; Vartanian JP; Wain-Hobson S
    PLoS One; 2013; 8(6):e63461. PubMed ID: 23840298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.